Digital health

Recent experience includes:


In addition to our longstanding role advising UCB in relation to a range of day-to-day trading agreements (including MSAs, Platform Technology collaborations and Sponsored Research Agreements), we recently advised in relation to a contract with Enable Injections, Inc., for the development and clinical supply of a wearable injection device for the delivery of rozanolixizumab, an investigational antibody for the treatment of Myasthenia Gravis, a neuromuscular disease causing weakness in skeletal muscles. We have also advised UCB in business development projects including a licensing deal in the digital health space and UCB’s compliance with Human Samples legislation and GDPR.

International pharma company

Advised in relation to a collaboration with Verily Sciences, the Google Life Sciences company, for the use of Verily’s wearable technology as part of clinical trial programme.

Management sellers of Health iQ

Advised the sellers of Health iQ, a leading provider in real world data and digital solutions for healthcare and life sciences, on its sale by way of auction process to Corrona LLC, a US leader in real world evidence. We provided the entire range of legal advice, from tax through to IP, throughout the auction process, working hand in hand with Deloitte to facilitate the sale.

Optum Venture Global Partners, LP

Advised Optum, as the lead investor, investing by way of subscription for Series A Shares, in Oxford VR Limited, resulting in Optum holding 20% of the fully diluted share capital in Oxford VR. Oxford VR is technology company which has developed immersive virtual reality software aimed at treating mental health issues such as anxiety.

Healthcare apps

Advised a global healthcare company on its mobile healthcare/related apps.